Related references
Note: Only part of the references are listed.The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study
Jason A. Roberts et al.
CLINICAL INFECTIOUS DISEASES (2021)
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing
Milo Gatti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Does dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review
Suzanne L. de Vroom et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance
David P. Nicolau et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration
Fekade B. Sime et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Advances in the therapy of bacterial bloodstream infections
M. Giannella et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies
Nieves Carbonell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam
Jianguo Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin
Pratik Bhagunde et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections
Jordan R. Smith et al.
PHARMACOTHERAPY (2020)
Ceftolozane-tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study
Edward Raby et al.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY (2020)
The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms
Mandee Noval et al.
CURRENT INFECTIOUS DISEASE REPORTS (2020)
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Mohd H. Abdul-Aziz et al.
INTENSIVE CARE MEDICINE (2020)
Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy
Lu Li et al.
FRONTIERS IN PHARMACOLOGY (2020)
Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base
Mohd H. Abdul-Aziz et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2020)
An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
Eric Wenzler et al.
INFECTIOUS DISEASES AND THERAPY (2020)
Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature
Mary Sheffield et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
New beta-Lactam-beta-Lactamase Inhibitor Combinations
Dafna Yahav et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
Renal Dosing of Antibiotics: Are We Jumping the Gun?
Ryan L. Crass et al.
CLINICAL INFECTIOUS DISEASES (2019)
Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia
Shampa Das et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis
Wesley D. Kufel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Augmented Renal Clearance
Aaron M. Cook et al.
PHARMACOTHERAPY (2019)
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms
Pranita D. Tamma et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2019)
A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy
Valentina Pistolesi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
John O'Donnell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment
Richard A. Preston et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically III Patients without Renal Dysfunction
Fekade B. Sime et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review
Chandra Datta Sumi et al.
CLINICAL PHARMACOKINETICS (2019)
Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience
Daniel C. Richter et al.
INFECTION (2019)
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Marin H. Kollef et al.
LANCET INFECTIOUS DISEASES (2019)
Pharmacokinetics/Pharmacodynamics of β-Lactams and Therapeutic Drug Monitoring: From Theory to Practical Issues in the Intensive Care Unit
Paul Williams et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic/pharmacodynamic target in Asian ICU population: a prospective observational study
Chien-Chih Wu et al.
INFECTION AND DRUG RESISTANCE (2019)
Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin
Takayuki Katsube et al.
CLINICAL INFECTIOUS DISEASES (2019)
The Pharmacodynamics of Prolonged Infusion β-Lactams for the Treatment of Pseudomonas aeruginosa Infections: A Systematic Review
Abrar K. Thabit et al.
CLINICAL THERAPEUTICS (2019)
Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration
Paige Soukup et al.
PHARMACOTHERAPY (2019)
Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem
David C. Griffith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment
Richard A. Preston et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Extended Infusion of β-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study
Michele Bartoletti et al.
CLINICAL INFECTIOUS DISEASES (2019)
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience
Matteo Bassetti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients
Gary E. Stein et al.
SURGICAL INFECTIONS (2019)
Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections
Pratik Bhagunde et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration
Gerardo Aguilar et al.
CRITICAL CARE (2019)
Optimization of the treatment with beta-lactam antibiotics in critically ill patientsguidelines from the French Society of Pharmacology and Therapeutics (Societe Francaise de Pharmacologie et TherapeutiqueSFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Societe Francaise d'Anesthesie et ReanimationSFAR)
Romain Guilhaumou et al.
CRITICAL CARE (2019)
MIC-based dose adjustment: facts and fables
Johan W. Mouton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Avibactam Pharmacokinetic/Pharmacodynamic Targets
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis
Nao Kawaguchi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment
Christopher M. Rubino et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis
Nathaniel J. Rhodes et al.
CRITICAL CARE MEDICINE (2018)
Prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials
Konstantinos Z. Vardakas et al.
LANCET INFECTIOUS DISEASES (2018)
Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam
Fekade B. Sime et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Suboptimal Clinical Response Rates with Newer Antibiotics Among Patients with Moderate Renal Impairment: Review of the Literature and Potential Pharmacokinetic and Pharmacodynamic Considerations for Observed Findings
Monique R. Bidell et al.
PHARMACOTHERAPY (2018)
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink et al.
INFECTIOUS DISEASES AND THERAPY (2018)
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-beta-Lactamase Inhibitor Combinations
George G. Zhanel et al.
DRUGS (2018)
Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy
Matthew Rawlins et al.
CHEMOTHERAPY (2018)
Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment
Henri Merdjan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy
Caleb J. P. Economou et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial
Andrew A. Udy et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L
Senthil Natesan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration
Eric Wenzler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease
Alan J. Xiao et al.
INFECTIOUS DISEASES AND THERAPY (2017)
Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration
Wesley D. Oliver et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
Alan J. Xiao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis A Meta-analysis of Individual Patient Data from Randomized Trials
Jason A. Roberts et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
John E. Mazuski et al.
CLINICAL INFECTIOUS DISEASES (2016)
Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis
Mohd H. Abdul-Aziz et al.
INTENSIVE CARE MEDICINE (2016)
Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration
Joseph L. Kuti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
Antimicrobial Resistance
Hilary D. Marston et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
n Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy
Derek N. Bremmer et al.
PHARMACOTHERAPY (2016)
Therapeutic drug monitoring of anti-infective agents in critically ill patients
Nynke G. L. Jager et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Joseph Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2015)
Optimization of dosing regimens and dosing in special populations
F. B. Sime et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
Optimizing dosing of antibiotics in critically ill patients
Suzanne L. Parker et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2015)
To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt
Wai-Tat Wong et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?
Janattul-Ain Jamal et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2015)
Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study
Angela Huttner et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Subtleties in practical application of prolonged infusion of β-lactam antibiotics
Jan J. De Waele et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial
Fekade Bruck Sime et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics
Athena L. V. Hobbs et al.
PHARMACOTHERAPY (2015)
Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development
Mohd H. Abdul-Aziz et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
The effect of pathophysiology on pharmacokinetics in the critically ill patient - Concepts appraised by the example of antimicrobial agents
Stijn I. Blot et al.
ADVANCED DRUG DELIVERY REVIEWS (2014)
Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam
Myra Wooley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?
Gloria Wong et al.
BMC INFECTIOUS DISEASES (2014)
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
Jason A. Roberts et al.
CLINICAL INFECTIOUS DISEASES (2014)
Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial
Jan J. De Waele et al.
INTENSIVE CARE MEDICINE (2014)
Mortality Related to Severe Sepsis and Septic Shock Among Critically III Patients in Australia and New Zealand, 2000-2012
Kirsi-Maija Kaukonen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
Jason A. Roberts et al.
LANCET INFECTIOUS DISEASES (2014)
Stability of Generic Meropenem Solutions for Administration by Continuous Infusion at Normal and Elevated Temperatures
Loretta Franceschi et al.
THERAPEUTIC DRUG MONITORING (2014)
Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy
Barbara O. M. Claus et al.
JOURNAL OF CRITICAL CARE (2013)
Severe Sepsis and Septic Shock REPLY
Derek C. Angus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Severe Sepsis and Septic Shock
Derek C. Angus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Subtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients Association Between Augmented Renal Clearance and Low Trough Drug Concentrations
Andrew A. Udy et al.
CHEST (2012)
Comparative Activity of Carbapenem Testing (COMPACT) study in Germany
Giuseppe Valenza et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics
Jason A. Roberts et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review
Fekade Bruck Sime et al.
ANNALS OF INTENSIVE CARE (2012)
Antibiotic Dosing in Multiple Organ Dysfunction Syndrome
Marta Ulldemolins et al.
CHEST (2011)
Appropriateness is Critical
Marta Ulldemolins et al.
CRITICAL CARE CLINICS (2011)
Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock
Anand Kumar et al.
CHEST (2009)
Pharmacokinetic issues for antibiotics in the critically ill patient
Jason A. Roberts et al.
CRITICAL CARE MEDICINE (2009)
Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock - does the dose matter?
Federico Pea et al.
CRITICAL CARE (2009)
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock
Arland Kumar et al.
CRITICAL CARE MEDICINE (2006)
Acute renal failure in critically ill patients - A multinational, multicenter study
S Uchino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'
GL Drusano
NATURE REVIEWS MICROBIOLOGY (2004)
Comparative stability studies of antipseudomonal β-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)
E Viaene et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients
H Servais et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Share Paper
